How to Pick the Best Cancer Proteins for a Vaccine
This patent describes a method for choosing specific proteins from diseased cells, like cancer cells, to create personalized vaccines by checking if the body already reacts to them or if they bind to certain cell components.
Original patent title: “Methods for predicting the usefulness of proteins or protein fragments for immunotherapy”
This patent describes a method for choosing specific proteins from diseased cells, like cancer cells, to create personalized vaccines by checking if the body already reacts to them or if they bind to certain cell components. Owned by UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG -UNIVERSITÄT MAINZ with 22 claims, and it is expected to expire in 2044.
Coverage
What does this patent actually cover?
The patent describes a method for making vaccines, especially for personalized cancer treatment. It involves identifying specific proteins or protein pieces from diseased cells that would be useful for immunotherapy. This identification step, as per claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 20, checks for one or more of three things: (a) if the body already has antibodies against these proteins, (b) if these proteins bind to a cell structure called F-actin, or (c) if they bind to RNA. If any of these conditions are met, it suggests the protein or its genetic code is a good candidate for a vaccine. The method then involves manufacturing a vaccine containing these selected proteins or their genetic instructions. For example, if a patient's tumor cells express a unique protein that the patient's immune system has already started to make antibodies against, that protein would be selected for inclusion in a personalized vaccine (claim 20a).
The gap
What does this patent NOT cover?
- Does not cover selecting vaccine components solely based on their presence in diseased cells without checking for antibody response, F-actin binding, or RNA binding.
- Does not cover methods for making vaccines that do not involve determining these specific binding or response properties of the proteins.
- Does not cover vaccines made from proteins that are not expressed by diseased cells, as specified in claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 20.
- Does not cover general vaccine manufacturing processes that do not incorporate this specific protein selection methodology.
- Does not cover immunotherapy approaches that do not involve a vaccine, such as direct antibody infusions or CAR-T cell therapy.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The noveltynoveltyThe requirement that an invention be different from anything publicly known before its priority date.Read more → lies in using specific indicators—an existing antibody response, or the binding of a protein to F-actin or RNA—as a way to predict which tumor proteins will be most effective at triggering an immune response when used in a vaccine. This moves beyond simply identifying tumor-specific proteins to selecting those with a higher likelihood of being "useful for immunotherapy" (claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 20).
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Personalized mRNA cancer vaccines
Neoantigen-based cancer immunotherapies
Vaccines for solid tumors
Individualized cancer treatment plans
Why it matters
The bigger picture
This patent is significant for the field of personalized cancer immunotherapy. By providing a specific method to identify highly immunogenic (immune-stimulating) proteins from a patient's own tumor, it aims to improve the effectiveness of cancer vaccines. This approach could lead to vaccines that are precisely tailored to an individual's unique cancer, potentially reducing side effects and increasing treatment success compared to more general cancer therapies.
Filed
October 18, 2024
Market context
Who's building on this
Companies in this space
BioNTech, co-founded by inventorinventorThe person who actually conceived the invention. Listed on the patent regardless of who owns it.Read more → Ugur Sahin, is a leading company in mRNA vaccine technology and personalized cancer immunotherapies, actively developing neoantigen-specific vaccines. Moderna also has programs in personalized cancer vaccines. Other biotech companies and academic institutions are heavily invested in this area, focusing on identifying and utilizing tumor-specific antigens for therapeutic purposes.
Market impact
This type of research and patenting contributes to the rapidly expanding market for personalized medicine, particularly in oncology. It helps define methods for developing highly specific cancer vaccines, which could lead to new product lines and treatment paradigms. The focus on identifying effective neoantigens is crucial for improving patient outcomes and has spurred significant investment and competition in the biopharmaceutical industry.
Claim 1 — Plain English
What this patent covers
The patent describes a method for making vaccines, especially for personalized cancer treatment. It involves identifying specific proteins or protein pieces from diseased cells that would be useful for immunotherapy. This identification step, as per claim 20, checks for one or more of three things: (a) if the body already has antibodies against these proteins, (b) if these proteins bind to a cell structure called F-actin, or (c) if they bind to RNA. If any of these conditions are met, it suggests the protein or its genetic code is a good candidate for a vaccine. The method then involves manufacturing a vaccine containing these selected proteins or their genetic instructions. For example, if a patient's tumor cells express a unique protein that the patient's immune system has already started to make antibodies against, that protein would be selected for inclusion in a personalized vaccine (claim 20a).
The clever bit
The novelty lies in using specific indicators—an existing antibody response, or the binding of a protein to F-actin or RNA—as a way to predict which tumor proteins will be most effective at triggering an immune response when used in a vaccine. This moves beyond simply identifying tumor-specific proteins to selecting those with a higher likelihood of being "useful for immunotherapy" (claim 20).
What it does not cover
- Does not cover selecting vaccine components solely based on their presence in diseased cells without checking for antibody response, F-actin binding, or RNA binding.
- Does not cover methods for making vaccines that do not involve determining these specific binding or response properties of the proteins.
- Does not cover vaccines made from proteins that are not expressed by diseased cells, as specified in claim 20.
- Does not cover general vaccine manufacturing processes that do not incorporate this specific protein selection methodology.
- Does not cover immunotherapy approaches that do not involve a vaccine, such as direct antibody infusions or CAR-T cell therapy.
Patent timeline
Application submitted to the patent office
Patent enters public domain
PatentBrief Score
Impact Score
Limited data
Citation count
0/40
No citations yet
Claim breadth
15/20
Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
0/20
Older than 20 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$29K – $94K
Midpoint $59K · 17.9 yr remaining · industry ×1.5
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
22 claims as filed with the patent office.
Concepts involved
Cite this patent
Sahin, U., Vormehr, M., Löwer, M., Schrörs, B., & Boegel, S. How to Pick the Best Cancer Proteins for a Vaccine (U.S. Patent No. 20,250,244,311). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20250244311/methods-for-predicting-the-usefulness-of-proteins-or-protein-fragments-for-immun
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US20250244311"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 10377797 · 2019 · Immatics Biotechnologies
Training Immune Cells to Fight Cancer Using Specific Markers
US 10314897 · 2019 · Immatics Biotechnologies
How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer
US 12734225 · 2026
New Peptide Vaccines for Fighting Cancer
US 12006349 · 2024 · Immatics Biotechnologies
How a Specific Peptide Can Train Your Immune System to Fight Cancer
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does How to Pick the Best Cancer Proteins for a Vaccine cover?
This patent describes a method for choosing specific proteins from diseased cells, like cancer cells, to create personalized vaccines by checking if the body already reacts to them or if they bind to certain cell components.
Who owns patent US 20250244311?
This patent is owned by UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG -UNIVERSITÄT MAINZ.
When does this patent expire?
This patent is expected to expire on October 18, 2044, when the invention enters the public domain.
What problem does this patent solve?
This patent is significant for the field of personalized cancer immunotherapy. By providing a specific method to identify highly immunogenic (immune-stimulating) proteins from a patient's own tumor, it aims to improve the effectiveness of cancer vaccines. This approach could lead to vaccines that are precisely tailored to an individual's unique cancer, potentially reducing side effects and increasing treatment success compared to more general cancer therapies.
What does this patent NOT cover?
Does not cover selecting vaccine components solely based on their presence in diseased cells without checking for antibody response, F-actin binding, or RNA binding.
Patent monitoring





